Icosapent

Introduction Overview

Generic Name

icosapent

Brand Name

Vascepa, Icosapent Ethyl

Dosage Form

oral capsule (0.5 g; 1 g)

Drug Class

Miscellaneous antihyperlipidemic agents

Pharmacokinetics

Absorption: Icosapent ethyl, a potent purified ethyl ester of eicosapentaenoic acid (EPA), is well absorbed after oral administration. Peak plasma concentrations of EPA are usually achieved within 5 hours following ingestion of a single dose with food, which enhances absorption substantially. The bioavailability can be affected by the meal composition, especially fat content, with high-fat meals increasing plasma exposure. It is recommended to administer icosapent with food to optimize absorption. Clinical studies have documented consistent plasma levels with twice-daily dosing.

Distribution: After absorption, icosapent is extensively distributed, with EPA incorporated into various plasma lipid pools including phospholipids, triglycerides, cholesteryl esters, and free fatty acids. It is also incorporated into cell membranes of various tissues, which may underlie some of its long-term biological effects. Plasma protein binding is significant, predominantly to albumin, facilitating transport through the circulation. The volume of distribution reflects incorporation into lipid compartments and cell membranes, influencing duration of action.

Metabolism: Icosapent ethyl undergoes rapid hydrolysis by plasma and hepatic esterases to release free EPA. EPA is a long-chain omega-3 polyunsaturated fatty acid metabolized primarily via beta-oxidation in mitochondria and peroxisomes predominantly in the liver. It undergoes conversion to various bioactive metabolites such as resolvins and prostaglandin derivatives, which contribute to anti-inflammatory and cardioprotective effects. The metabolic fate is influenced by enzymatic pathways including cytochrome P450 enzymes, with minimal involvement of CYP isoforms, resulting in a low propensity for metabolic drug interactions.

Elimination: EPA and its metabolites are eliminated primarily through beta-oxidation with end products excreted via urine and feces. The elimination half-life of EPA after icosapent administration is variable, with a terminal half-life estimated at approximately 89 hours, reflecting incorporation into membrane phospholipids and slow turnover. Steady-state plasma levels are attained after approximately 4 weeks of consistent dosing. Renal excretion accounts for a minor elimination route. Clinical pharmacokinetic studies indicate no significant accumulation with twice daily dosing in patients with normal hepatic or renal function, but caution is advised in severe hepatic impairment where metabolism and clearance might be altered.

Dosage Forms

Available Dosage Forms:
- Oral capsule 0.5 g
- Oral capsule 1 g

Dosages for Adults and Adolescents:
- The recommended dose is 2 grams orally twice daily with food, allowing for a total daily dose of 4 grams EPA ethyl ester.
- Used as adjunctive therapy with diet to reduce triglyceride levels in patients with severe hypertriglyceridemia (≥500 mg/dL).
- Also approved as adjunct to maximally tolerated statin therapy to reduce risk of major cardiovascular events in adult patients with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus with additional risk factors.

Specific Patient Populations:
- Use in patients under 18 years of age is not approved.
- Limited pharmacokinetic data exist in severe hepatic or renal impairment; dosing adjustments are not formally established, thus caution is advised.
- Pregnancy and lactation: Safety has not been established; consultation is necessary.
- Patients with fish or shellfish allergies should avoid use due to potential hypersensitivity reactions.

Clinical Guidelines:
- Administer capsules whole; do not crush, chew, break, or open.
- Take with food to improve absorption.
- Monitor lipid profiles periodically to assess therapeutic response.
- Integrate within a comprehensive cardiovascular risk reduction strategy including diet and lifestyle modifications.

Mechanism Of Action

Icosapent ethyl consists primarily of the ethyl ester of eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid. Upon ingestion, it is hydrolyzed to EPA, which exerts multiple biochemical and physiological effects relevant to lipid metabolism and cardiovascular risk reduction. The primary molecular mechanism involves modulation of triglyceride synthesis and clearance via hepatic and peripheral pathways.

At the cellular level, EPA modifies lipid homeostasis by decreasing hepatic very-low-density lipoprotein (VLDL) triglyceride synthesis and secretion. This is thought to result from EPA's ability to inhibit diacylglycerol acyltransferase, a key enzyme in triglyceride biosynthesis, and promoting beta-oxidation of fatty acids, thereby reducing substrate availability for triglyceride production. Furthermore, EPA enhances lipoprotein lipase activity, facilitating the clearance of triglyceride-rich lipoproteins from the circulation.

Biochemically, EPA serves as a substrate for cyclooxygenase and lipoxygenase pathways, generating anti-inflammatory and vasodilatory eicosanoids such as resolvins and protectins. These metabolites contribute to reduced vascular inflammation and plaque stabilization, integral to cardiovascular protection. EPA also inhibits platelet aggregation and reduces oxidative stress, further contributing to cardioprotective effects.

Clinically, these mechanisms translate into significant reductions in fasting triglyceride levels and a demonstrated reduction in rates of major adverse cardiovascular events when used adjunctively with statins in specific patient populations. Comparative studies suggest that EPA's benefits are pronounced compared to mixed omega-3 formulations containing docosahexaenoic acid (DHA), possibly due to distinct effects on lipid profiles and inflammation. Large randomized controlled trials have substantiated its efficacy in secondary prevention of cardiovascular disease in high-risk patients.

Pharmacological Actions

Reduction of serum triglyceride levels in patients with severe hypertriglyceridemia.
Adjunctive lipid-modifying therapy reducing very-low-density lipoprotein (VLDL) production and enhancing triglyceride clearance.
Anti-inflammatory effects mediated via EPA-derived eicosanoids (resolvins and protectins).
Improvement of endothelial function and vascular health through antioxidant mechanisms.
Inhibition of platelet aggregation, contributing to antithrombotic properties.
Reduction of oxidative stress and modulation of lipid peroxidation pathways.
Potential stabilization of atherosclerotic plaques reducing cardiovascular event risk.
Synergistic action with statins to reduce residual cardiovascular risk in patients with elevated triglycerides.
Minimal interference with LDL cholesterol levels, distinguishing it from some lipid-lowering agents.
Favorable safety profile with minimal impact on coagulation parameters at therapeutic doses.

Therapeutic Or Clinical Uses

Adjunct therapy to reduce triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL).
Adjunct to maximally tolerated statin therapy for reducing the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in patients with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease.
Risk reduction of major adverse cardiovascular events in high-risk adult populations.
Part of a comprehensive management plan incorporating diet and lifestyle modification for hyperlipidemia.
Use in combination with a low-fat and low-cholesterol diet to optimize lipid control.
Exploratory use in reducing inflammatory markers associated with cardiovascular diseases.
Potential use in patients intolerant to other antihyperlipidemic agents as a supplementary treatment.
Investigational use for modulation of metabolic parameters in diabetic dyslipidemia.
Adjunctive option for patients requiring further triglyceride lowering despite statin therapy.
May contribute to stabilization of atherosclerotic plaques, potentially reducing progression of cardiovascular disease.

Side Or Adverse Effects

Muscle or joint pain (myalgia or arthralgia), which may occasionally affect patient compliance.
Constipation, reported among common gastrointestinal side effects.
Peripheral edema manifested as swelling of hands, legs, or feet.
Gout or hyperuricemia, due to potential effects on uric acid metabolism.
Chest discomfort, including pressure sensation or palpitations such as racing or pounding heartbeats and fluttering in the chest.
Potential for serious bleeding events, especially when coadministered with anticoagulants or antiplatelet agents.
Rare instances of allergic reactions including hives, swelling, and respiratory difficulty.
Dizziness and fainting episodes potentially indicative of arrhythmias or hypotension.
Gastrointestinal upset including nausea or dyspepsia reported less frequently.
Possible elevation in liver enzymes; however, clinically significant hepatotoxicity is rare.
Fatigue or malaise reported anecdotally in some patients.
Hypersensitivity reactions in patients allergic to fish or shellfish may occur.
No significant alterations in fasting glucose or HbA1c in diabetic patients generally observed.
Potential increase in bleeding time necessitating monitoring in patients on concomitant blood thinners.

Precautions

Assess patient history for hypersensitivity to fish, shellfish, or any component of the formulation before initiation.
Monitor for signs of bleeding, particularly in patients concurrently receiving anticoagulants or antiplatelet therapy.
Exercise caution in patients with a known bleeding or clotting disorder.
Use with vigilance in patients with hepatic impairment as metabolism may be altered.
Pregnancy and breastfeeding status should be ascertained; safety has not been established in these populations.
Not approved for use in pediatric patients under 18 years of age.
Regular monitoring of lipid levels and cardiovascular status is necessary to evaluate efficacy and safety.
Adherence to prescribed dietary and exercise regimens is critical for optimal therapeutic effects.
Use cautiously in patients with diabetes mellitus; monitor glycemic control as part of routine care.
Educate patients to swallow capsules whole and take with food to maximize absorption and minimize gastrointestinal discomfort.
Patients should be informed about potential side effects and advised to report any unexplained bleeding or cardiac symptoms.
Avoid sudden discontinuation without medical advice to prevent rebound lipid elevations.
Concurrent use with other lipid-lowering agents should be managed carefully to avoid additive side effects.
Evaluate renal function in patients with underlying kidney disease, although no dosage adjustment has been established.
Careful assessment is warranted in elderly patients, who may be more susceptible to adverse effects.

Warnings

Do not use icosapent if allergic to icosapent or fish/shellfish products due to risk of severe hypersensitivity reactions.
Monitor for serious bleeding events; discontinue or adjust coadministered anticoagulants as clinically indicated.
Report any signs of allergic reactions immediately, including hives, swelling, or respiratory distress.
May cause atrial fibrillation or arrhythmias in rare cases—prompt evaluation required if palpitations or dizziness occur.
Follow all medication instructions exactly and avoid crushing or chewing capsules to prevent altered pharmacokinetics.
Potential increased risk of bleeding in patients undergoing invasive procedures; consult healthcare provider accordingly.
The effect of icosapent on pancreatitis risk in patients with severe hypertriglyceridemia has not been established; continued monitoring warranted.
Do not exceed recommended doses; overdose may lead to adverse cardiac or bleeding complications.
This medication is not a substitute for lifestyle modifications and should be integrated into a comprehensive care plan.
Avoid abrupt discontinuation to prevent potential rebound elevations in triglyceride levels.
Report any new or worsening cardiovascular symptoms promptly.
Not approved for pediatric use; safety and effectiveness in this population have not been demonstrated.
Use caution when combining with other lipid-modifying therapies to avoid additive adverse effects.
Storage conditions: keep at room temperature away from moisture and heat to maintain drug efficacy.
Healthcare providers should evaluate drug interactions carefully, especially with blood thinners and other cardiovascular agents.

Contraindication

Known hypersensitivity to icosapent, eicosapentaenoic acid, or any component of the formulation.
Allergy to fish or shellfish products due to risk of severe allergic reactions.
Severe hepatic impairment where metabolism and clearance are significantly compromised (use with extreme caution or avoid).
Active bleeding disorders or hemorrhagic tendencies contraindicate use due to enhanced bleeding risk.
Concomitant use with other agents known to substantially increase bleeding risk without close monitoring.
Patients with history of recurrent pancreatitis not related to hypertriglyceridemia until risk/benefit is assessed.
Not indicated for use in pediatric patients under 18 years of age.
Known sensitivity to omega-3 fatty acid products or excipients in the capsule formulation.
Contraindicated in patients with substantial intolerance or severe adverse response to previous icosapent therapy.
Use is not recommended in pregnancy or breastfeeding in absence of compelling indication and medical supervision.

Drug Interactions

Increased bleeding risk when coadministered with anticoagulants such as warfarin, Coumadin, or Jantoven.
Potential additive effects on platelet function when used with antiplatelet agents (aspirin, clopidogrel).
Minimal interaction with statins; commonly coadministered but monitoring lipid parameters and liver enzymes is recommended.
No significant interactions reported with common antihypertensive agents, though clinical judgment advised.
Limited evidence of interaction with cytochrome P450 metabolized drugs due to minimal CYP involvement in metabolism.
Concomitant use with other omega-3 fatty acid supplements may increase risk of adverse effects, especially bleeding.
Potential interaction with immunosuppressants via modulation of inflammatory pathways has not been fully elucidated.
No clinically significant interaction observed with common antidiabetic agents.
Caution advised when used with nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive bleeding potential.
No notable interference with oral contraceptives or hormone replacement therapies documented.
Patients on other lipid-modifying agents should be monitored for efficacy and toxicity.
Potential interaction with herbal supplements affecting coagulation (e.g., ginkgo biloba, garlic) may enhance bleeding risk.
Adherence to pharmacist and physician guidance for all concomitant medications is essential for safety.
No evidence of interference with common psychotropic or cardiovascular drugs affecting heart rhythm.
Ensure thorough medication reconciliation to identify potential interactions prior to initiating therapy.

Preparations Of The Drug

Icosapent Ethyl oral capsules are available in 0.5 gram and 1 gram strengths.
Available under the brand name Vascepa.
Formulated as ethyl esters of eicosapentaenoic acid for improved stability and bioavailability.
Capsules are intended for oral administration and must be swallowed whole.
Packaged to protect from moisture and heat; stored at controlled room temperature conditions.
Formulation contains inert excipients suitable for oral use; does not contain gluten or lactose.
Prescribed as part of adjunctive lipid-lowering therapy regimens.
Marketed as a prescription-only medication requiring professional medical oversight.
Manufactured with rigorous quality control according to current Good Manufacturing Practices (cGMP).
Available in blister packs or bottles, depending on market and regulatory approvals.
Manufacturer instructions emphasize administration with food to promote absorption.
No injectable or alternative dosage forms currently available for icosapent.
Typically dispensed along with patient medication guides highlighting adherence and safety.
Packaging includes labeling with dosage instructions, warnings, and contraindications.
Prescription labeling provides information on potential side effects and drug interactions.